Enzyme–Prodrug Therapies of Cancer

Richard J. Knox, Roger G. Melton, Ronit Satchi*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Since the early twentieth century, many researchers have sought Ehrlich’s elusive magic bullet for treating the ills of mankind. The principle of chemotherapy has depended on a compound exhibiting selective toxicity towards a foreign organism. With respect to cancer chemotherapy, it was envisaged that compounds would be identified or synthesized that would be able to distinguish between normal and neoplastic cells and selectively correct or eradicate the abnormal cells with minimal toxic side effects on normal cells and tissue. Cancer chemotherapy has rarely achieved this.

Original languageEnglish
Title of host publication Polymeric Biomaterials, Revised and Expanded
EditorsSeverian Dumitriu
Place of PublicationBoca Raton
PublisherCRC Press
Pages895-927
Edition2nd
ISBN (Electronic)9780203904671
DOIs
StatePublished - 2001

Fingerprint

Dive into the research topics of 'Enzyme–Prodrug Therapies of Cancer'. Together they form a unique fingerprint.

Cite this